PD-L1+ tumors showed an increase in type I/II IFN signaling and lymphoid signatures across tumor groups, as described previously within single tumor types, while PD-L1− tumors showed increased in metabolic pathways and zinc finger proteins. The gene discussed is ZNF146; the disease is neoplasm.